本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Ventyx Biosciences, Inc.

3.56
-0.3000-7.77%
盤後3.50-0.0600-1.69%18:55 EDT
成交量:147.40萬
成交額:533.27萬
市值:2.54億
市盈率:-2.12
高:3.88
開:3.86
低:3.48
收:3.86
52周最高:4.05
52周最低:0.7830
股本:7,130.85萬
流通股本:5,355.59萬
量比:0.89
換手率:2.75%
股息:- -
股息率:- -
每股收益(TTM):-1.6773
每股收益(LYR):-1.9732
淨資產收益率:-48.56%
總資產收益率:-30.23%
市淨率:1.21
市盈率(LYR):-1.80

資料載入中...

2023/05/31

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2023/05/15

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2023/05/11

重要事件披露

8-K - Current report
2023/05/11

季度報告

10-Q - Quarterly report [Sections 13 or 15(d)]
2023/05/05

關聯方擬減持公告

144 - Report of proposed sale of securities
2023/05/03

關聯方擬減持公告

144 - Report of proposed sale of securities
2023/05/03

關聯方擬減持公告

144 - Report of proposed sale of securities
2023/04/28

關聯方擬減持公告

144 - Report of proposed sale of securities
2023/04/07

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2023/03/23

重要事件披露

8-K - Current report
2023/03/23

年度報告

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2023/03/22

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2023/03/02

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2023/02/14

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/01/30

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2023/01/26

重要事件披露

8-K - Current report
2023/01/12

重要事件披露

8-K - Current report
2023/01/05

員工持股計劃

S-8 - Securities to be offered to employees in employee benefit plans
2022/12/30

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/12/20

重要事件披露

8-K - Current report